Med Life S.A. operates as a private healthcare provider in Romania.
Med Life Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||RON19.85|
|52 Week High||RON6.33|
|52 Week Low||RON20.20|
|1 Month Change||16.08%|
|3 Month Change||16.42%|
|1 Year Change||211.78%|
|3 Year Change||341.11%|
|5 Year Change||n/a|
|Change since IPO||358.08%|
Recent News & Updates
Does Med Life (BVB:M) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Med Life's (BVB:M) Returns On Capital Are Heading Higher
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Here's Why We Think Med Life (BVB:M) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|M||RO Healthcare||RO Market|
Return vs Industry: M exceeded the RO Healthcare industry which returned 9.6% over the past year.
Return vs Market: M exceeded the RO Market which returned 42.4% over the past year.
Stable Share Price: M is not significantly more volatile than the rest of RO stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: M's weekly volatility (4%) has been stable over the past year.
About the Company
Med Life S.A. operates as a private healthcare provider in Romania. It operates through six business lines: Corporate, Clinics, Laboratories, Hospitals, Pharmacies, and Stomatology. The Corporate business line offers health prevention packages to corporate clients, which cover regular check-ups and access to diagnostic services.
Med Life Fundamentals Summary
|M fundamental statistics|
Is M overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|M income statement (TTM)|
|Cost of Revenue||RON539.32m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.84|
|Net Profit Margin||8.57%|
How did M perform over the long term?See historical performance and comparison
Is Med Life undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: M (RON19.85) is trading below our estimate of fair value (RON40.96)
Significantly Below Fair Value: M is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: M is poor value based on its PE Ratio (23.5x) compared to the European Healthcare industry average (23.2x).
PE vs Market: M is poor value based on its PE Ratio (23.5x) compared to the RO market (14.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate M's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: M is overvalued based on its PB Ratio (8.6x) compared to the XE Healthcare industry average (2.3x).
How is Med Life forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if M's forecast earnings growth is above the savings rate (1.2%).
Earnings vs Market: Insufficient data to determine if M's earnings are forecast to grow faster than the RO market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: M's revenue (8.1% per year) is forecast to grow faster than the RO market (5.4% per year).
High Growth Revenue: M's revenue (8.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: M's Return on Equity is forecast to be high in 3 years time (23%)
How has Med Life performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: M has high quality earnings.
Growing Profit Margin: M's current net profit margins (8.6%) are higher than last year (1.6%).
Past Earnings Growth Analysis
Earnings Trend: M's earnings have grown significantly by 76% per year over the past 5 years.
Accelerating Growth: M's earnings growth over the past year (607.3%) exceeds its 5-year average (76% per year).
Earnings vs Industry: M earnings growth over the past year (607.3%) exceeded the Healthcare industry 40.8%.
Return on Equity
High ROE: Whilst M's Return on Equity (36.41%) is high, this metric is skewed due to their high level of debt.
How is Med Life's financial position?
Financial Position Analysis
Short Term Liabilities: M's short term assets (RON347.8M) do not cover its short term liabilities (RON355.2M).
Long Term Liabilities: M's short term assets (RON347.8M) do not cover its long term liabilities (RON573.1M).
Debt to Equity History and Analysis
Debt Level: M's debt to equity ratio (149.6%) is considered high.
Reducing Debt: M's debt to equity ratio has reduced from 215.2% to 149.6% over the past 5 years.
Debt Coverage: M's debt is well covered by operating cash flow (33.4%).
Interest Coverage: M's interest payments on its debt are well covered by EBIT (7.6x coverage).
What is Med Life current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate M's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate M's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if M's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if M's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of M's dividend in 3 years as they are not forecast to pay a notable one for the RO market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mihail Marcu (51 yo)
Mr. Mihail Marcu serves as Chief Executive Officer at S.C. Med Life S.A. since December 2016. Mr. Marcu served as the Chief Executive Officer of MedLife between January 2004 until August 2006 and vice pres...
Experienced Management: M's management team is considered experienced (4.8 years average tenure).
Experienced Board: M's board of directors are seasoned and experienced ( 13.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Med Life S.A.'s employee growth, exchange listings and data sources
- Name: Med Life S.A.
- Ticker: M
- Exchange: BVB
- Founded: 1996
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: RON2.611b
- Shares outstanding: 131.53m
- Website: https://www.medlife.ro
Number of Employees
- Med Life S.A.
- Calea Grivitei, No. 365
- District 1
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 16:45|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.